| Description | BMS CCR2 22 is a potent and selective antagonist of CCR2 with calcium flux IC50 of 18 nM, chemotaxis IC50 of 1 nM, and binding IC50 of 5.1 nM. |
| In vitro | BMS CCR2 22 inhibits the internalization of hMCP1_AF647 (IC50 = 2 nM)[2]. HAoECs with BMS CCR2 22 before MCP-1 increases the cell surface levels of VCAM-1 from 72.8 to 160% and PECAM1 from 97.2 and 127%[3]. |
| Target activity | CCR2:5.1 nM |
| molecular weight | 593.66 |
| Molecular formula | C28H34F3N5O4S |
| CAS | 445479-97-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 225.0 mg/mL (379.0 mM), Sonication is recommended. |
| References | 1. Cherney RJ, et al. Discovery of disubstituted cyclohexanes as a new class of CC chemokine receptor 2 antagonists. J Med Chem. 2008 Feb 28;51(4):721-4. 2. Kredel S, et al. High-content analysis of CCR2 antagonists on human primary monocytes. J Biomol Screen. 2011 Aug;16(7):683-93. 3. D'Antoni ML, et al. Cenicriviroc inhibits trans-endothelial passage of monocytes and is associated with impaired E-selectin expression. J Leukoc Biol. 2018 Dec;104(6):1241-1252. |